In addition, miR-23a showed high expression in lung cancer stem cells, and down-regulation of miR-23a could enhance the antitumor effects of erlotinib by increasing PTEN expression to regulate the PI3K/Akt pathway (39). The gene discussed is AKT1; the disease is lung carcinoma.